Updated Jul 16, 2026 · Last SEC filing 2026-06-17
Acumen Pharmaceuticals, Inc. (ABOS) has filed 10 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-17. 3 Form 8-K material event filings were reported by ABOS in the last 90 days. 4 Form 144 notices of proposed sale were filed for ABOS stock. InsiderAlpha tracks every ABOS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001576885 |
|---|
| Form 4 filings (90d) | 10 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 4 |
| Latest Form 4 filing | 2026-06-17 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director | M — Option exercise | 13.0K | $1.07 | $14K | SEC | |
| Porter Derrell | Director | S — Open-market sale | 13.0K | $2.33 | $30K | SEC | |
| Porter Derrell | Director | S — Open-market sale | 12.8K | $2.33 | $30K | SEC | |
| Porter Derrell | Director | S — Open-market sale | 6.5K | $2.35 | $15K | SEC | |
| Porter Derrell | Director | M — Option exercise | 6.5K | $1.07 | $7K | SEC | |
| Fountain Nathan B | Director | S — Open-market sale | 6.4K | $2.23 | $14K | SEC | |
| Ives Jeffrey L. | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Golumbeski George | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Porter Derrell | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Stalfort John A III | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Fountain Nathan B | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| RA CAPITAL MANAGEMENT, L.P. | Insider | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Drapkin Kimberlee C | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| Stoppel Laura | Director | A — Grant or award | 35.5K | $0.00 | — | SEC | |
| RA CAPITAL MANAGEMENT, L.P. | Insider | A — Grant or award | 6.06M | $3.30 | $20.00M | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Acumen Pharmaceuticals, Inc. (ABOS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Porter Derrell | 9 | $96K |
| Fountain Nathan B | 3 | $14K |
| Golumbeski George | 2 | — |
| Stalfort John A III | 2 | — |
| Drapkin Kimberlee C | 2 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ABOS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ABOS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.